Mr. Paul Duffy reports

AIML ALIGNS LEADERSHIP FOR GROWTH AND SHAREHOLDER VALUE CREATION

AI-ML Innovations Inc. has provided key updates to its board of directors as the company enters an exciting new phase of growth and commercialization.

Paul Duffy, AI-ML's chief executive officer, and Peter Kendall, AI-ML's president and chief commercialization officer, have both been appointed to the board. Mr. Duffy has also assumed the role of executive chairman, Simultaneously, Mark Orsmond, outgoing executive chair of the board, and Michael Nemirow have stepped down from the board and continue their involvement as strategic advisers.

These changes reflect AI-ML's strategic commitment to aligning with the company's forward-looking focus on commercial execution, market penetration and strategic partnerships. As AI-ML continues to advance its innovative portfolio of AI-driven health care technologies, this board realignment ensures the company is structured to accelerate growth, provide direct industry experience and drive shareholder value.

Mr. Duffy, CEO and newly appointed chairman of the board, commented: "We are entering an exciting new chapter at AI-ML, one defined by focus, execution and scalable impact. Strengthening our board with more industry participants to enhance a commercialization lens is a key part of our strategic evolution, and I'm honoured to now serve in a governance capacity alongside Peter Kendall. I would like to express my deep gratitude to both Mark and Michael for their dedication, insights and leadership during a foundational period for the company. In particular, we are very grateful to Mark for the top-tier medical and professional team that is now part of our company, and I look forward to continuing to work closely with him in his new advisory role."

As part of this transition, Mr. Orsmond and Mr. Nemirow will continue to play a pivotal role in the company's growth trajectory, supporting corporate development initiatives, strategic partnerships and commercialization strategies.

AI-ML remains steadfast in its mission to deliver breakthrough solutions at the intersection of artificial intelligence and human health. These leadership transitions mark a meaningful step forward in realizing that vision.

About AI-ML Innovations Inc.

AI-ML Innovations has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and well-being companies that leverage AI, ML, cloud computing and digital platforms to drive transformative health care management solutions and precision support delivery across the health continuum. Through its acquisition of Quantum Sciences Ltd. (100 per cent owned by AI-ML) and NeuralCloud Solutions Inc. (100 per cent owned by AI-ML), strategic partnerships with Health Gauge Inc. (95.2 per cent owned by AI-ML), Tech2Heal (up to 22-per-cent ownership rights, with 11.11 per cent currently owned by AI-ML) and AI Rx Inc. (70 per cent owned by AI-ML), and other planned accretive investments, the company continues to capitalize on expanding growth areas, to the benefit of all the company's stakeholders. AI-ML's shares are traded on the Canadian Securities Exchange under the symbol AIML, on the OTCQB Venture Market under AIMLF and on the Frankfurt Stock Exchange under 42FB.

We seek Safe Harbor.